Previous 10 | Next 10 |
Esperion Therapeutics, Inc. (ESPR) Q2 2020 Earnings Conference Call August 10, 2020 04:30 PM ET Company Participants Ben Church - Corporate Communications Tim Mayleben - President & Chief Executive Officer Mark Glickman - Chief Commercial Officer Rick Bartram - Chief Financ...
The following slide deck was published by Esperion Therapeutics, Inc. in conjunction with their 2020 Q2 earnings Read more ...
Esperion Therapeutics (NASDAQ: ESPR ) : Q2 GAAP EPS of $4.32 beats by $2.09 . More news on: Esperion Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
– Highest Quarterly and First Half Total Revenue in Company History with $214 million in Total YTD Revenue – – Strong Capital Position with over $300 Million in Cash – – Extraordinary High-Quality Managed Care Coverage with Over 80% Com...
ANN ARBOR, Mich., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2020 financial results after the close of the U.S. financial markets on August 10, 2020. Following the release, company management will host a webcast and conference cal...
Revenue clarity and accelerating growth in the middle of recession suggests top stocks deserve premium valuations, but stocks don't rise or fall in a straight line, so expecting some form of mean reversion is understandable. That said, stocks tend to climb higher and fall further than most...
ANN ARBOR, Mich., July 01, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that pooled efficacy analysis from the four Phase 3 clinical studies of NEXLETOL, an oral, once-daily LDL-cholesterol lowering medicine, was published in the Journal of the American Medical Associat...
Esperion Therapeutics, Inc. ( ESPR ) focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). Its Bempedoic acid, market name Nexletol, along with its sister medication Nexlizet (a combination of Bempedoic...
Esperion to Receive $150 Million Milestone Payment in June Esperion Completes Transfer of Marketing Authorization Approvals (MAAs) for NILEMDO™ (bempedoic acid) and NUSTENDI™ (bempedoic acid and ezetimibe) Tablets to DSE DSE to Initiate Commer...
Never underestimate the appeal of stupidity said with conviction. " - Kevin Focke Today, we revisit Esperion Therapeutics ( ESPR ) we had as an option play of the week in mid-November to Biotech Forum members exclusively via a simple covered call strategy. The shares shot up from $4...
News, Short Squeeze, Breakout and More Instantly...
Esperion Therapeutics Inc. Company Name:
ESPR Stock Symbol:
NASDAQ Market:
Esperion Therapeutics Inc. Website:
ANN ARBOR, Mich., July 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2024 financial results before the market opens on Monday, August 12, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financi...
ANN ARBOR, Mich., July 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the BTIG Biotech Conference on Monday, August 5, 2024, at 4 p.m. ET. Esperion Therapeutics At Esperion, we discover, develop, and commercialize innovat...
– Targeted Campaign Reaches Patients at Risk for Heart Attack or Heart Procedures Because of High LDL Cholesterol (LDL-C) – – Animated Characters Are a Visual Representation of An Unseen Risk “Lurking” In Patients’ Artery Walls &...